SS-3PROSPECTIVE OBSERVATIONAL STUDY ON CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING FOR PATIENTS WITH COLORECTAL CANCER IN JAPAN

Abstract Purpose: This study is performed to investigate the incidence of cemotherapy-induced nausea and vomiting (CINV) for patients (pts) with colorectal cancer received moderately emetogenic chemotherapy. We also assessed whether the medical staff accurately recognized the incidence of CINV in practices. Methods: A prospective observational study of patients receiving the first cycle of oxaliplatin or irinotecan-based chemotherapy was performed. A 7-day diary for CINV was provided to the patients, and the incidence of CINV was recorded daily by themselves. The observed incidence rates of CINV in acute (day1) and delayed (days2-7) were compared with the medical staff's predictions. Results: A total of 191 pts were registered between April 2011 and December 2012. All pts were treated with oxaliplatin-based (n = 175) or irinotecan-based chemotherapy (n = 16). Acute vomiting episode was observed in 4 pts (2.1%), while delayed vomiting was observed in 19 pts (10%). Acute nausea occurred in 14 pts (7.3%), while delayed nausea occurred in 63 pts (33%). Irinotecan significantly induced acute nausea more frequently than oxaliplatin (P = 0.019). The presence of motion sickness was significantly associated with the incidence of acute nausea (P Conclusions: CINV seems to be controllable with appropriate management, but delayed CINV remains an important problem. The presence of motion sickness should be affected by efficient antiemetic management. The extent of CINV in this patient group seems to be overestimated.